Health Catalyst vs Tempus
Side-by-side comparison of AI visibility scores, market position, and capabilities
$307M revenue 2024 (up from $296M 2023); $316M TTM Jun 2025; $26M adjusted EBITDA; 100M+ patient records; expects double-digit growth 2025; low-20s net new platform clients 2024; healthcare analytics leader
About
Health Catalyst is a healthcare data and analytics company founded in 2008 in Salt Lake City, Utah, built on the mission of being a catalyst for massive, measurable, data-informed improvement in the health of humanity. The company's core technology — the Health Catalyst Data Operating System (DOS) — provides healthcare organizations with a cloud-based data platform that aggregates clinical, financial, and operational data from disparate source systems into a unified analytics environment designed specifically for the complexity of healthcare data.\n\nHealth Catalyst serves 40+ health systems and hundreds of hospitals, offering analytics applications, embedded data science teams, and technology-enabled services that help organizations improve quality outcomes, reduce costs, and optimize operations. Its suite includes applications for perioperative efficiency, population health management, sepsis surveillance, and financial analytics. The company differentiates through a unique Tech-Enabled Managed Services model, embedding data scientists alongside health system teams to ensure analytics drive measurable operational change rather than sitting unused.\n\nHealth Catalyst generated $307M in revenue in 2024, up from $296M in 2023, with $26M in adjusted EBITDA and a database of over 100 million patient records. As a publicly traded company (HCAT), it has built one of the largest healthcare-specific analytics platforms in the US. With regulatory pressure, value-based care contracts, and margin compression intensifying across health systems, Health Catalyst's integrated data platform and domain expertise position it as a strategic partner for health systems pursuing data-driven operational transformation.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
About
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.